Editorial
Copyright ©2012 Baishideng Publishing Group Co.
World J Cardiol. May 26, 2012; 4(5): 135-147
Published online May 26, 2012. doi: 10.4330/wjc.v4.i5.135
Table 5 Therapeutic strategies
Non-pharmacological strategy
Weight reduction
Dietary sodium reduction
Physical activity
Moderate alcohol consumption
Dash diet
Pharmacological strategy
Main Pharmacological agents
Thiazide diuretic: inhibiting reabsorption of sodium (Na+) and chloride (Cl-) ions from the distal convoluted tubules in the kidneys →→↓ BP, ↓ stroke, ↓ CV mortality
ACEIs: block the conversion of angiotensin I to angiotensin II →→↓ SVR, ↓ BP, ↓ mortality in patients with MI and left ventricular dysfunction, ↓ progression of diabetic renal disease
ARBs: direct blockage of angiotensin II receptors →→ vasodilation (↓SVR), ↓ secretion of vasopressin, ↓ aldosterone, ↓ BP, ↓ stroke. Generally, in patients who cannot tolerate ACEs
Calcium antagonists: disrupts the movement of calcium through calcium channels in cardiac muscle and peripheral arteries →→ vasodilation (↓ SVR), ↓ BP, ↓ CV complications in elderly patients with ISH
β blockers: ↓ heart rate, ↓ cardiac contractility, ↓ cardiac output, inhibit renin release, ↑ nitric oxide, ↓ vasomotor tone →→↓ BP
Other agents: direct renin inhibitors, aldosterone receptor antagonists, centrally acting agents, direct vasodilators, α-adrenergic blocking agents
Combination therapy
ACEIs or ARBs/Diuretic
ACEIs or ARBs/Calcium antagonist (especially in patients with high CV risk)